2:48
ESH MM 2018 | Genomics shed light on targeted treatment for myeloma
Nikhil Munshi
1:39
ESH MM 2018 | Are BCL2 and MCL1 inhibitors the key against myeloma?
Enrique Ocio
1:56
ESH MM 2018 | Mapping the genomic landscape of Waldenström’s Macroglobulinemia
Steven Treon
1:25
EORTC CLTF 2018 | Insight into CTCL intratumor heterogeneity may inform disease management
Robert Gniadecki
2:03
EORTC CLTF 2018 | New molecular targets for cutaneous T-cell lymphoma therapy
Chalid Assaf
3:48
EORTC CLTF 2018 | Normal and neoplastic stem cells: from discovery to treatments
Irving Weissman
3:00
EORTC CLTF 2018 | Regulation of PD-L1 in cutaneous lymphoma by miRNAs
Christiane Querfeld
2:47
SOHO 2018 | Molecular background studies to aid diagnosis and treatment of MDS
Torsten Haferlach
5:06
SOHO 2018 | Personlized therapy for MDS: Advancements and the future
Torsten Haferlach
2:45
SOHO 2018 | Identifying genetic mutations for diagnosing MDS
Torsten Haferlach
4:31
SOHO 2018 | Limitations of targeted therapy for AML
Harry Erba
4:42
SOHO 2018 | Gene-based treatments show positive outcomes in AML
Harry Erba
12:32
iwNHL 2018 | iwNHL 2018 day 1 highlights: T-cells, biomarkers & personalized medicine
Catherine Bollard et al.
2:28
SOHO 2018 | Updates on the survival rates of MLL treatments
Rob Pieters
1:53
SOHO 2018 | Using inflammation to detect and monitor MDS
Valeria Santini
1:26
SOHO 2018 | Future directions for MLL therapy
Rob Pieters
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals